Literature DB >> 23186009

Unraveling the mechanisms involved in endothelial barrier protective effects of angiopoietin-1 variant MAT.Ang-1.

Ru-Yuan Zhang, Dong Min, Jun Wu, Lei Li, Hong-Ping Qu, Yao-Qing Tang.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23186009      PMCID: PMC3672586          DOI: 10.1186/cc11844

Source DB:  PubMed          Journal:  Crit Care        ISSN: 1364-8535            Impact factor:   9.097


× No keyword cloud information.

With great interest we read the recent article by Alfieri and colleagues [1], demonstrating that angiopoietin (Ang)-1 variant MAT.Ang-1 improved endotoxemiainduced microvascular dysfunction and microvascular hyperpermeability. The authors suggested that MAT. Ang-1-induced recovery of microcirculatory tissue perfusion during sepsis is due to preservation of endothelial barrier integrity. To further elucidate the mechanism, they investigated the possibility of involvement of VE-cadherin, a major adherens junctions protein responsible for microvascular leakage in inflammation. They found, however, while there was no change in overall expression of VE-cadherin, MAT.Ang-1 increased VE-cadherin phosphorylation in the treated mice, which appears unable to explain the observed endothelial barrier protective effects of MAT.Ang-1. The work by Dejana and co-workers [2] highlights the critical role of VE-cadherin for maintenance of endothelial barrier function. It is generally accepted that the tyrosine phosphorylation of VE-cadherin and other components of adherens junctions induced by permeability-increasing agents is associated with weak junctions and impaired barrier function via regulating VE-cadherin member localization [2]. Recently, among the nine tyrosines in the cytoplasmic tail of VE-cadherin, Potter and colleagues [3] revealed that tyrosine phosphorylation of VE-cadherin at two critical tyrosines, Tyr-658 and Tyr-731, was sufficient to disrupt VE-cadherin-mediated cell-cell junctions, leading to inhibition of cell barrier function. Previous studies have shown that Ang-1 restores the endothelial barrier function via phosphorylation-dependent redistribution of VE-cadherin [4,5]. While in the present study the total amount of VE-cadherin was not changed, intriguingly MAT.Ang-1 increases VE-cadherin phosphorylation (at Y658) in sepsis. This is unexpected because the endothelial barrier protective effects of MAT.Ang-1 do not seem to be consistent with its effect on an important cellular junction molecule involved in endothelial cell integrity, namely VE-cadherin; however, other mechanisms of action cannot be ruled out. Nevertheless, further studies are needed to investigate the mechanisms by which this novel Ang-1 variant rescues the endothelial barrier function.

Authors' response

Alessio Alfieri, Nicola J Brown and Zoe L Brookes We appreciate the interest and insightful comments made by Zhang and colleagues concerning our recent research article. The functional in vivo studies presented in our manuscript demonstrated that MAT.Ang-1 reduced macromolecular leak and improved tissue perfusion without significantly changing the diameter of microvessels, thus suggesting that the protective effects induced by MAT.Ang-1 depend on preserving the endothelial barrier integrity. In addition to the well-recognized role in controlling vascular permeability, VE-cadherin and associated junctional proteins form part of complex signaling cascades regulating important cellular functions [6]. In particular, as discussed in our manuscript, disassembly of the VE-cadherin complex triggers an intracellular negative signal reducing transendothelial leukocyte migration in mice 6 hours after challenge with lipopolysaccharide [7]. Therefore, an increase in VE-cadherin phosphorylation paralleled by reduced interleukin-1β protein expression may be a mechanism by which MAT.Ang-1 induces protection against microvascular stasis in sepsis. Furthermore, lipopolysaccharide-induced endotoxemia increases the expression of several inflammatory cytokines (for example, tumor necrosis factor-α), which in turn cause macromolecular leak [8]. Therefore, in vivo a complex mechanistic scenario develops in sepsis with regards to the endothelial barrier function, which is difficult to unravel. The elegant studies referenced by Zhang and colleagues concerning Ang-1 and VE-cadherin phosphorylation report in vitro findings, whereas all our results are from septic mice in vivo with or without MAT.Ang-1 post-treatment. Nevertheless, we agree that further investigations are required before making firm conclusions on the effects of MAT.Ang-1 on the endothelium in sepsis - for instance, studies aimed at providing a complete in vivo time-course of the expression, localization and phosphorylation of endothelial junctional proteins would be extremely informative.

Abbreviations

Ang: angiopoietin.

Competing interests

The authors declare that they have no competing interests.
  8 in total

1.  Angiopoietin-1 protects heart against ischemia/reperfusion injury through VE-cadherin dephosphorylation and myocardiac integrin-β1/ERK/caspase-9 phosphorylation cascade.

Authors:  Sae-Won Lee; Joo-Yun Won; Hae-Young Lee; Ho-Jae Lee; Seock-Won Youn; Ji-Young Lee; Chung-Hyun Cho; Hyun-Jai Cho; Seil Oh; In-Ho Chae; Hyo-Soo Kim
Journal:  Mol Med       Date:  2011-07-05       Impact factor: 6.354

2.  Regulation of lung neutrophil recruitment by VE-cadherin.

Authors:  Janie Orrington-Myers; Xiaopei Gao; Panos Kouklis; Michael Broman; Arshad Rahman; Stephen M Vogel; Asrar B Malik
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2006-06-16       Impact factor: 5.464

Review 3.  VE-cadherin: at the front, center, and sides of endothelial cell organization and function.

Authors:  Elizabeth S Harris; W James Nelson
Journal:  Curr Opin Cell Biol       Date:  2010-08-11       Impact factor: 8.382

4.  Angiopoietin-1 is an antipermeability and anti-inflammatory agent in vitro and targets cell junctions.

Authors:  J R Gamble; J Drew; L Trezise; A Underwood; M Parsons; L Kasminkas; J Rudge; G Yancopoulos; M A Vadas
Journal:  Circ Res       Date:  2000-09-29       Impact factor: 17.367

5.  Tyrosine phosphorylation of VE-cadherin prevents binding of p120- and beta-catenin and maintains the cellular mesenchymal state.

Authors:  Matthew D Potter; Simone Barbero; David A Cheresh
Journal:  J Biol Chem       Date:  2005-07-18       Impact factor: 5.157

Review 6.  The role of adherens junctions and VE-cadherin in the control of vascular permeability.

Authors:  Elisabetta Dejana; Fabrizio Orsenigo; Maria Grazia Lampugnani
Journal:  J Cell Sci       Date:  2008-07-01       Impact factor: 5.285

Review 7.  Inflammatory cytokines in vascular dysfunction and vascular disease.

Authors:  Alexander H Sprague; Raouf A Khalil
Journal:  Biochem Pharmacol       Date:  2009-05-04       Impact factor: 5.858

8.  Angiopoietin-1 variant reduces LPS-induced microvascular dysfunction in a murine model of sepsis.

Authors:  Alessio Alfieri; Jay J Watson; Richard A Kammerer; Mohammed Tasab; Pavlos Progias; Kimberly Reeves; Nicola J Brown; Zoe L Brookes
Journal:  Crit Care       Date:  2012-10-04       Impact factor: 9.097

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.